Budesonide and Albuterol Inhaler Comparison for Asthma

This study is exploring whether a new type of inhaler propellant, called HFO, works as well as the current propellant, HFA, in delivering a combination asthma medication known as BDA. This medication is used to help manage asthma symptoms. The study's aim is to ensure that people with asthma can receive their medication effectively with the new propellant, which might have environmental or practical benefits over the current one. Understanding this will help ensure that asthma treatments remain effective while potentially improving safety or environmental impact. Participants in the study will be involved for about 14 to 15 weeks. Initially, there is a 2-week period to screen participants and prepare them with a placebo. Then, they will undergo three different treatment phases, each lasting 4 weeks. During these phases, the participants will use inhalers with either the current or new propellant. Regular clinic visits will occur every 2 to 4 weeks to monitor treatment effects and ensure safety. A follow-up call will happen about 5 days after the last treatment to check on the participants' well-being. The study is designed to closely monitor the effectiveness of the inhaler propellants in delivering asthma medication safely.